Breast Cancer Cohort Will Track Whether Cognitive Decline Tracks With Chronic Pain
A prospective French cohort is asking a question that has long sat at the bedside but rarely been tested directly: does cancer treatment-induced cognitive impairment help drive chronic pain in women treated for breast cancer? The Cactus study is built to examine that link over one year, following patients from surgery through chemotherapy and into the months after treatment ends.
The premise is clinically plausible. Chemotherapy can alter attention, working memory, executive function, and other cognitive domains often grouped under the umbrella of “chemo brain,” while persistent pain after breast cancer therapy can become its own disabling syndrome. If cognitive impairment changes how pain is perceived, processed, remembered, or managed, then the interaction could explain why some patients remain stuck with lasting pain long after active treatment has ended.
Why Pain and Cognition Are Being Studied Together
Cactus focuses on women with non-metastatic, hormone receptor-positive breast cancer who have not previously received chemotherapy. That restriction is deliberate. It reduces the chance that pre-existing neurotoxic exposure blurs the relationship between treatment-related cognition and later pain. Participants are enrolled in the adjuvant setting after surgery and receive a standardized sequence of surgery, anthracycline- and taxane-based chemotherapy, radiotherapy, and endocrine therapy.
The study’s primary question centers on whether a significant change in the Global Composite Score, measured 6 months after chemotherapy ends, predicts a higher prevalence of chronic pain over the following year. Chronic pain is defined here as persistent pain intensity of at least 4. The neuropsychological construct is broad and intentionally so: the Global Composite Score combines eight measures spanning long-term memory, inhibition, cognitive flexibility, verbal fluency, nonverbal fluency, working memory, and phasic attention.
A single-sentence reality frames the whole protocol: pain and cognition may be traveling on the same neurobiological road.
What the Investigators Will Measure at Each Time Point
Follow-up is scheduled at three points. T1 occurs before chemotherapy but after surgery. T2 falls after chemotherapy completion, within a 2-week window. T3 comes 6 months after chemotherapy, within a 1-week window. Those time points are not incidental. They let investigators compare pain and cognitive status immediately after treatment and again after a longer recovery interval, when lingering symptoms may either fade or harden into chronicity.
The primary endpoint is straightforward: compare the percentage of patients with chronic pain between those with and without cognitive impairment at T3. Secondary analyses extend the same comparison to T2, giving an early snapshot soon after chemotherapy ends. The study will also compare chronic pain characteristics and pain-related disability, including etiology, incidence, severity, localization, and disability burden.
Pain phenotyping is unusually detailed for an observational registry. Investigators plan to use the Brief Pain Inventory, McGill Pain Questionnaire, DN4, NPSI, and a body diagram. Together, those tools can help distinguish nociceptive pain from neuropathic features, map pain distribution, and capture how much pain interferes with function.
A Detailed Cognitive-Pain Phenotype May Matter More Than a Single Score
The protocol does not stop at global cognitive impairment. It also asks whether specific domains matter more than others. Cognitive test scores used to build the Global Composite Score will be compared in patients with chronic pain, making it possible to ask whether deficits in certain functions, such as working memory or inhibition, are more closely tied to pain persistence than others.
That question is biologically sensible. Cognitive control influences attention to bodily symptoms, the ability to reframe nociceptive input, and the execution of coping strategies. If inhibitory control weakens, pain may command more attention. If working memory or cognitive flexibility suffers, patients may struggle to apply learned coping skills consistently, especially under the stress of cancer recovery.
The study also includes patient-reported cognitive complaints through the FACT-Cog and WMQ questionnaires. Those measures matter because objective testing and subjective complaints often diverge in survivorship care. Someone may score within one range on neuropsychological testing yet still describe a meaningful cognitive burden in daily life. The protocol is set up to compare chronic pain prevalence in patients with complaints versus those without complaints at T2 and T3.
Fatigue, Mood, Sleep, and Coping Are Built Into the Same Framework
Pain after breast cancer does not appear in isolation, and the protocol reflects that reality. Investigators will evaluate fatigue with the MFI, sleep disturbances with the PSQI, and anxiety and depressive symptoms with the HADS. Pain coping strategies will be assessed with the Coping Strategies Questionnaire.
Those measures are more than background variables. Fatigue can amplify pain sensitivity and reduce activity tolerance. Poor sleep can lower pain thresholds and worsen symptom persistence. Anxiety and depressive symptoms can intensify perceived pain and complicate rehabilitation. By collecting these domains at both T2 and T3, the study may help separate transient treatment effects from more durable symptom clusters that reinforce one another.
One sentence captures the bedside concern: persistent pain rarely arrives alone.
Eligibility Narrowing Creates a More Homogeneous Cohort
The eligibility criteria aim for a clinically uniform population. Participants must be female, 35 to 65 years old, able to read and understand French, and affiliated with the French social security system or an entitled beneficiary. They must have non-metastatic, hormone receptor-positive breast cancer, no prior chemotherapy exposure, and a treatment pathway that includes surgery, anthracycline- and taxane-based chemotherapy, radiotherapy, and hormone therapy.
Several exclusions sharpen the signal the investigators want to measure. Patients with central nervous system disorders, major psychiatric illness, current use of higher-dose tricyclic antidepressants, benzodiazepines, or antipsychotics, morbid obesity, substance abuse within the prior six months, or chronic pain conditions before enrollment are excluded. An MMSE score below 26 triggers exclusion after the inclusion visit. These criteria reduce confounding, but they also create a cohort that is narrower than the broader breast cancer population seen in everyday practice.
Practical Consequences for Survivorship Care
The study’s potential clinical value lies in triage. If cognitive impairment tracks with chronic pain, then survivorship programs may need to screen both domains together rather than treating them as separate aftereffects of cancer therapy. The protocol already anticipates such a pathway: patients with chronic pain may be referred to specialized pain centers, while those with cognitive impairment may be directed to a Memory Resource and Research Center, speech therapists, or neuropsychologists.
No therapeutic intervention is being tested here, and no efficacy claim can be made yet. The study is observational, prospective, and set to enroll an estimated 182 participants. Its start date is listed as 2026-01-09, with primary completion estimated for 2027-01 and study completion estimated for 2028-03.
For now, the value of Cactus is in its structure. It treats cognition not as a side effect floating separately from pain, but as a possible contributor to the chronic pain phenotype after breast cancer treatment. If that association is confirmed, the implications would reach from neuropsychological screening to pain referral pathways and survivorship follow-up design.